TGFβ/ACTIVIN-SMAD2/3-EZH2 cooperates with OCT4 and NANOG in self-renewing hPSCs to keep CDKIs in an epigenetically poised state for rapid activation. Upon the initiation of endoderm differentiation ...
Lung cancer is the leading cause of cancer death worldwide and even today only 10% of people survive lung cancer for 10 years or more in the UK. One challenge in treating lung cancer is that lung ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Measuring COVID-19's impact on diagnosis of cervical cancer by race/ethnicity, age, and region of the United States. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Worldwide, more than a million breast cancer patients have been treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which slow or stop the uncontrolled multiplication of cancer cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results